Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 76

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 76
---
Changes in operating assets and liabilities:        Decrease in prepaid expenses  255,913   167,360 Decrease in inventory  235,731   (116,193)Decrease in accounts payable and accrued liabilities  (198,867)  (822,258)Decrease in lease liability  (158,698)  (152,228)Net cash used in operating activities  (7,400,547)  (9,548,775)         Cash Flows from Investing Activities        Purchases of fixed assets  (16,000)  (33,884)Proceeds from sale of fixed assets  3,204   9,163 Net cash used in investing activities  (12,796)  (24,721)         Cash Flows from Financing Activities        Proceeds from issuance of common stock  1,148,470   6,483,393 Proceeds from warrant issuances and exercises  6,688,930   1,034,912 Repayment of loan  (28,484)    Net cash provided by financing activities  7,808,917   7,518,305          Net increase (decrease) in cash  395,573   (2,055,191)         Cash, beginning of period  2,833,907   4,889,098          Cash, end of period $3,229,480  $2,833,907          Supplemental disclosures of cash items        Interest paid $31,910  $44,985 Income tax paid $-  $-          Supplemental disclosures of non-cash items        Stock dividend payable $(5,233) $840 Right of use asset $578,013  $354,091 Lease liability $584,419  $365,919 Cashless warrants $3,076,664  $- 

The accompanying notes are an integral part of these consolidated financial statements.

ENDRA Life Sciences Inc.

Notes to Consolidated Financial Statements

For the years ended December 31, 2024 and 2023

Note 1 - Nature of the Business ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) is designing a medical device for